# Drie urine-biomarkers verbeteren CKD-voorspelling naast KFRE — EMPA-KIDNEY

*geplaatst 2026-09-10 · Hartfalen · Clinical journal of the American Society of Nephrology : CJASN · doi 10.2215/CJN.0000001203 · https://hartvaat.nl/2026/09/03/drie-urine-biomarkers-verbeteren-ckd-voorspelling-naast-kfre-empa-kidney/*

In een substudie van het EMPA-KIDNEY-randomisatieonderzoek (n=5100 patiënten met chronische nierziekte) onderzochten onderzoekers of negen urine-tubulaire biomarkers de voorspellende waarde van de Kidney Failure Risk Equation (KFRE) kunnen verbeteren. De toevoeging van drie specifieke biomarkers (MCP-1, KIM-1 en EGF) leidde tot een statistisch significante, zij het bescheiden, verbetering in discriminatie voor nierfalen (C-index +0,014) en nierziekteprogressie (+0,038). Deze bevindingen suggereren dat deze biomarkers een aanvullende rol kunnen spelen in de risicostratificatie van CKD-patiënten, hoewel de routinematige implementatie nog afhankelijk is van beschikbaarheid en klinische bruikbaarheid.

## English: Predictive Value of Urine Tubular Biomarkers on Kidney Outcomes: Observations from EMPA-KIDNEY.

In a substudy of the EMPA-KIDNEY trial (n=5100 CKD patients), researchers evaluated whether nine urine tubular biomarkers could enhance the predictive accuracy of the Kidney Failure Risk Equation (KFRE). Adding three biomarkers (MCP-1, KIM-1, and EGF) yielded a modest but significant improvement in discrimination for kidney failure (C-index difference +0.014) and disease progression (+0.038). While these markers may offer incremental value for risk stratification in cardiorenal and nephrology practice, routine clinical adoption will depend on assay standardisation and widespread availability.

## Abstract (original, from the publication)

BACKGROUND: Urine tubular biomarkers have previously been associated with chronic kidney disease (CKD) progression independently of estimated glomerular filtration rate (eGFR) and albuminuria. We evaluated whether nine urine tubular biomarkers could improve prediction of kidney failure beyond serum creatinine and urine albumin-to-creatinine ratio among adults with CKD. METHODS: Among 5100 participants in EMPA-KIDNEY, a randomized trial which assessed the effects of empagliflozin 10 mg versus matching placebo among patients with CKD at risk of progression, nine urine creatinine-indexed tubular biomarkers were measured including alpha-1 microglobulin, dickkopf-3, epidermal growth factor [EGF], interleukin-18, kidney injury molecule-1 [KIM-1], monocyte chemoattractant protein-1 [MCP-1], neutrophil gelatinase-associated lipocalin, uromodulin, and human cartilage glycoprotein-40. Outcomes were kidney disease progression ('treated kidney failure', renal death, or sustained ≥40% eGFR decline) and treated kidney failure (maintenance dialysis or kidney transplant). Relative to models based on the linear predictor of the kidney failure risk equation (KFRE), improvements in discrimination were estimated with further addition of the nine tubular biomarkers using absolute difference in Uno's C-index. RESULTS: Over median 3.5 years of follow-up, 1191 participants experienced kidney disease progression and 461 experienced treated kidney failure. KFRE demonstrated excellent discrimination for treated kidney failure [C-index 0.858 (0.840,0.874)] and moderate discrimination for kidney disease progression [0.724 (0.705,0.743)]. Addition of three biomarkers (MCP-1, KIM-1, and EGF) most strongly associated with CKD outcomes yielded some further improvement in predicting kidney failure [absolute difference 0.014 (0.009,0.024)] and kidney disease progression [0.038 (0.026,0.053)]. Prediction of kidney outcomes were only slightly improved when further expanding from three to all ning tubular biomarkers. CONCLUSION: In a wide range of causes of CKD, adding three urine tubular biomarkers (MCP-1, KIM-1, EGF) to KFRE improves estimates of risk of CKD progression.

Auteurs: Greco B Malijan, William G Herrington, Parminder K Judge, Rebecca J Sardell, Daniel Chapman, Michael Hill, Stewart Moffat, Doreen Zhu, Alfred K Cheung, Dominik Steubl, Martin J Landray, Christoph Wanner, Colin Baigent, Richard Haynes, Joachim H Ix, Natalie Staplin, Michael G Shlipak

---
Bron: Clinical journal of the American Society of Nephrology : CJASN, https://doi.org/10.2215/CJN.0000001203. Bijgewerkt 2026-09-04T01:04:30Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.